71 completed, 17 terminated, 15 unknown, 7 withdrawn. 24 Phase 2, 22 Phase 4, 18 Phase 3, 14 Not applicable, 11 Phase 1.
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis Terfenadine, Standard First-line Disease-Modifying Therapy - Relapsing Remitting Multiple Sclerosis | Phase 2 | Recruiting | Chuan Qin | 100 | 2026-08-15 | 2026-09-18 |
| The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation - Relapsing Remitting Multiple Sclerosis | Not applicable | Recruiting | SetPoint Medical Corporation | 60 | 2026-04-17 | 2026-09-02 |
| Cladribine Tablets as an Exit Therapy Strategy Cladribine - Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Completed | University Hospital, Strasbourg, France | 450 | 2025-10-17 | 2026-10-06 | |
| Administration of Fingolimod in Greek Patients With Multiple Sclerosis. Relapsing Remitting Multiple Sclerosis | Not yet recruiting | Elpen Pharmaceutical Co. Inc. | 140 | 2025-06-01 | 2025-05-02 | |
| Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis MS Care Platform (icobrain ms and icompanion ms) - Relapsing Remitting Multiple Sclerosis | Suspended | Hoffmann-La Roche | 500 | 2024-10-21 | 2026-07-20 | |
| Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple sonography - Relapsing Remitting Multiple Sclerosis | Unknown | Assiut University | 100 | 2024-08-01 | 2024-06-04 | |
| Serum Neurofilament Light in Multiple Sclerosis Serum Neurofilament Light - Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Active not recruiting | Dent Neuroscience Research Center | 42 | 2024-04-09 | 2025-02-14 | |
| Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis Blood samples - Relapsing Remitting Multiple Sclerosis | Not applicable | Unknown | University of Aarhus | 200 | 2023-11-27 | 2023-12-07 |
| Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis PIPE-307 Dose A, PIPE-307 Dose B, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Janssen Research & Development, LLC | 182 | 2023-11-06 | 2026-09-25 |
| Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice Monomethyl Fumarate - Relapsing Remitting Multiple Sclerosis | Terminated | Banner Life Sciences LLC | 25 | 2023-08-17 | 2025-03-06 | |
| A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Completed | Novartis | 113 | 2023-04-23 | 2024-05-02 | |
| Functional Outcomes From Diets in Multiple Sclerosis Glycemic load, Calorie restriction, Behavioral support - Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Not applicable | Active not recruiting | University of Alabama at Birmingham | 100 | 2023-03-20 | 2026-04-03 |
| Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis Eye-tracking - Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis | Unknown | McGill University | 120 | 2022-09-01 | 2023-11-09 | |
| Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis Eye tracking, Microperimetry, Optical coherence tomography (OCT) - Multiple Sclerosis, Clinically Isolated Syndrome | Enrolling by invitation | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | 120 | 2022-06-13 | 2025-05-16 | |
| Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures), Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) - Relapsing Remitting Multiple Sclerosis | Completed | Assiut University | 63 | 2022-03-01 | 2022-11-03 | |
| Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE Clinical assessment - Relapsing Remitting Multiple Sclerosis | Unknown | NHS Greater Glasgow and Clyde | 245 | 2022-02-07 | 2022-07-25 | |
| Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment Ofatumumab - Relapsing Remitting Multiple Sclerosis | Completed | University of Southern California | 40 | 2022-01-29 | 2026-05-06 | |
| Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis Relapsing Remitting Multiple Sclerosis | Completed | Firat University | 60 | 2021-11-01 | 2022-04-28 | |
| MS Relapses During COVID-19 Pandemic No Intervention - Multiple Sclerosis, Covid19 | Completed | Nottingham University Hospitals NHS Trust | 51 | 2021-07-01 | 2026-03-19 | |
| Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate monomethyl fumarate - Relapsing Remitting Multiple Sclerosis | Withdrawn | Banner Life Sciences LLC | 2021-06-30 | 2021-11-18 |
Showing 20 of 124. Sign in to see all of them.
Multiple Sclerosis, Relapsing-Remitting (124) · Multiple Sclerosis (46) · Multiple Sclerosis, Chronic Progressive (13) · Autoimmune Diseases (4) · Demyelinating Diseases (4) · Fatigue (4) · Nervous System Diseases (4) · Immune System Diseases (2) · Motor Activity (2) · Neurologic Manifestations (2) · Optic Nerve Diseases (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases (1) · COVID-19 (1)
Autoimmune Diseases of the Nervous System (123) · Demyelinating Autoimmune Diseases, CNS (123) · Immune System Diseases (122) · Autoimmune Diseases (120) · Demyelinating Diseases (120) · Nervous System Diseases (120) · Multiple Sclerosis (78) · Pathological Conditions, Signs and Symptoms (18) · Disease Attributes (14) · Chronic Disease (13) · Pathologic Processes (13) · Signs and Symptoms (5) · Behavior (3) · Cranial Nerve Diseases (3) · Central Nervous System Diseases (2)
Glatiramer Acetate (14) · Interferon beta-1a (12) · Fingolimod Hydrochloride (8) · Dimethyl Fumarate (6) · Natalizumab (5) · monomethyl fumarate (4) · ocrelizumab (4) · Interferon beta-1b (3) · Rituximab (3) · Simvastatin (3) · Vitamin A (3) · Alemtuzumab (2) · Blood Specimen Collection (2) · Cholecalciferol (2) · Cladribine (2)
Biogen (9) · Teva Branded Pharmaceutical Products R&D, Inc. (9) · Novartis Pharmaceuticals (7) · Tehran University of Medical Sciences (5) · Banner Life Sciences LLC (4) · Johns Hopkins University (4) · Assiut University (2) · Charite University, Berlin, Germany (2) · Haukeland University Hospital (2) · Hoffmann-La Roche (2) · Providence Health & Services (2) · Queen Mary University of London (2) · Rocky Mountain MS Research Group, LLC (2) · University of Southern California (2) · University of Virginia (2)
United States (49) · Germany (14) · Spain (12) · Poland (11) · United Kingdom (11) · Russia (10) · Canada (9) · France (9) · Italy (9) · Hungary (6) · Iran (6) · Ukraine (6) · Australia (5) · Czechia (5) · Israel (5)
Franck Rousseau, MD (2) · John F Foley, MD (2) · Kyle Smoot, MD (2) · Sama Bitarafan, MD, PhD student (2) · Aaron L Boster, MD (1) · Ali Akbar Saboor Yaraghi, PhD (1) · Anat Achiron, MD PhD (1) · Anne Cross, M.D. (1) · Anthony Reder, M.D. (1) · Anthony Traboulsee, MD (1) · Anwar M Ali, professor (1)
PMID 42663866, PMID 10773854, PMID 11074395, PMID 11405811, PMID 11594918, PMID 11911515, PMID 11955556, PMID 12051465, PMID 12218161, PMID 12244307, PMID 12785670, PMID 12814166, PMID 14967763, PMID 15824337, PMID 16193899, PMID 16678208, PMID 16982884, PMID 17409388, PMID 17683116, PMID 18201113, PMID 18256342, PMID 18272891, PMID 18344396, PMID 18398457, PMID 18572078, PMID 19262165, PMID 19361678, PMID 19413920, PMID 19416878, PMID 20070277, PMID 20166093, PMID 20227772, PMID 20437580, PMID 20488825, PMID 205724, PMID 21111490, PMID 21261965, PMID 21367665, PMID 21368231, PMID 21372112, PMID 21672300, PMID 21856936, PMID 21991951, PMID 22127692, PMID 22622860, PMID 23424159, PMID 23459569, PMID 23497281, PMID 23695501, PMID 23868508
2009 (2), 2017 (2), 2004 (1), 2005 (1), 2014 (1), 2016 (1), 2018 (1), R01NS051591 (1), U01NS045719 (1), UM1AI109565 (1)